Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505635 · ClinicalTrials.gov registry record · Phase 2
Biochemotherapy With Temozolomide for Metastatic Melanoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00505635: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00505635 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505635, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and thalidomide can help to control melanoma that has spread to other parts of the body. The safety of this treatment will also be studied.
Interventions
- DRUG Cisplatin
- DRUG Temozolomide
- DRUG Interleukin-2
- DRUG Velban
- DRUG Intron-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505635
The ClinicalTrials.gov registry entry for NCT00505635 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00505635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505635 about?
NCT00505635 is a clinical study titled "Biochemotherapy With Temozolomide for Metastatic Melanoma". The goal of this clinical research study is to learn if treatment with Temodar (temozolomide), Velban (vinblastine), Cisplatin, Proleukin (interleukin-2), Intron-A (interferon alpha), and thalidomide can help to control melanoma that has spread to other parts of the body. The safety of this treatmen...
What is the current status of trial NCT00505635?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2007-03. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00505635?
The interventions under investigation include: Cisplatin (DRUG), Temozolomide (DRUG), Interleukin-2 (DRUG), Velban (DRUG), Intron-A (DRUG).
Who is sponsoring clinical trial NCT00505635?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.